Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 11/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81873 | 0.85 | SLC22A2 (0.48) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL81653 | 0.84 | SLC22A2 (0.47) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL81057 | 0.84 | SLC22A2 (0.54) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22673106 | 0.84 | SLC22A2 (0.47) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL17005284 | 0.83 | SLC22A2 (0.47) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL17005301 | 0.83 | SLC22A2 (0.47) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL83235 | 0.81 | SLC22A2 (0.45) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL17748220 | 0.80 | SLC22A2 (0.46) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL17527382 | 0.80 | SLC22A2 (0.49) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL2238466 | 0.78 | SLC22A2 (0.51) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273065-B2 | Substituted pyrido[1',2':4,5]pyrazino[1,2-a]pyrimidines as HIV integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20150232479-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232479-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | SLC22A2 2899/4885CYP3A4 36/4885TMEM97 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.